Aprotinin does not prolong the Sonoclot aprotinin-insensitive activated clotting time

Dong, Y.; Nuttall, G.A.; Oliver, W.C.; Agarwal, S.; Ereth, M.H.

Journal of Clinical Anesthesia 19(6): 424-428


ISSN/ISBN: 0952-8180
PMID: 17967670
DOI: 10.1016/j.jclinane.2007.03.003
Accession: 051620905

Download citation:  

Article/Abstract emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

To determine whether a new Sonoclot-based, aprotinin-insensitive activated clotting time (aiACT) assay yields stable results over a broad range of aprotinin concentrations. Prospective trial conducted on in vitro blood samples. Tertiary-care teaching medical center. 19 healthy adult volunteers. Whole blood samples were collected from volunteers. Heparin (2 U/mL) and escalating concentrations of aprotinin of 160 to 500 kallikrein inhibitory units (KIU)/mL were added in vitro. Celite ACT, kaolin ACT, and aiACT assays were completed. The aiACT showed stable activated clotting time (ACT) results on heparinized, noncitrated blood with added aprotinin (P = nonsignificant). In contrast, celite ACT and kaolin ACT were greatly prolonged when aprotinin was added to heparinized, noncitrated, and citrated blood (P < 0.05). The aiACT had consistent results at all aprotinin concentrations (P = nonsignificant). Aprotinin (160, 320, and 500 KIU/mL) significantly prolongs the ACT value with celite and kaolin activators but not with the aprotinin-insensitive activator.